FDA Enforcement Discretion Hearing

Amanda Kabage, our Research Program Manager, spoke at a public FDA hearing to discuss the clinical evidence for safety and efficacy of FMT treatment for recurrent C. difficile patients under the FDA’s enforcement discretion policy. View Here.   Share this:Click...

Early Development of Material Preparation

Our protocols for material preparation developed gradually, evolving from crudely blended stool in the endoscopy suite to development of frozen, liquid preparations enriched for fecal microbiota. The early donor program was developed in parallel over several years....

Re-established GMP Manufacturing

We re-established GMP manufacturing independent of commercial funding in 2017 with the help of philanthropic funding from Achieving Cures Together, Hubbard Broadcasting Foundation, and Maslowski Charitable Trust. Share this:Click to share on Twitter (Opens in new...

Treatment of fulminant C. difficile infection

The FMT protocol for treatment of fulminant C. difficile infection was published in the Journal of Clinical Gastroenterology in September 2013. Click here to read more.     Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook...

Demonstration of Microbiota Engraftment

Demonstration of microbiota engraftment was central to the new terminology of what was formerly known by various names, e.g., fecal bacteriotherapy, to ‘Fecal Microbiota Transplantation’. The term was first used in December 2011. Click here.   Share...
© 2021 Regents of the University of Minnesota. All rights reserved. The University of Minnesota is an equal opportunity educator and employer. Privacy Statement